Skip to main content
Erschienen in: Cancer Causes & Control 3/2013

01.03.2013 | Original paper

How can we make cancer survival statistics more useful for patients and clinicians: An illustration using localized prostate cancer in Sweden

verfasst von: Sandra Eloranta, Jan Adolfsson, Paul C. Lambert, Pär Stattin, Olof Akre, Therese M-L. Andersson, Paul W. Dickman

Erschienen in: Cancer Causes & Control | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Studies of cancer patient survival typically report relative survival or cause-specific survival using data from patients diagnosed many years in the past. From a risk-communication perspective, such measures are suboptimal for several reasons; their interpretation is not transparent for non-specialists, competing causes of death are ignored and the estimates are unsuitable to predict the outcome of newly diagnosed patients. In this paper, we discuss the relative merits of recently developed alternatives to traditionally reported measures of cancer patient survival.

Methods

In a relative survival framework, using a period approach, we estimated probabilities of death in the presence of competing risks. To illustrate the methods, we present estimates of survival among 23,353 initially untreated, or hormonally treated men with intermediate- or high-risk localized prostate cancer using Swedish population-based data.

Results

Among all groups of newly diagnosed patients, the probability of dying from prostate cancer, accounting for competing risks, was lower compared to the corresponding estimates where competing risks were ignored. Accounting for competing deaths was particularly important for patients aged more than 70 years at diagnosis in order to avoid overestimating the risk of dying from prostate cancer.

Conclusions

We argue that period estimates of survival, accounting for competing risks, provide the tools to communicate the actual risk that cancer patients, diagnosed today, face to die from their disease. Such measures should offer a more useful basis for risk communication between patients and clinicians and we advocate their use as means to answer prognostic questions.
Literatur
1.
Zurück zum Zitat Dickman PW, Adami HO (2006) Interpreting trends in cancer patient survival. J Intern Med 260:103–117PubMedCrossRef Dickman PW, Adami HO (2006) Interpreting trends in cancer patient survival. J Intern Med 260:103–117PubMedCrossRef
2.
Zurück zum Zitat Perme MP, Stare J, Esteve J (2012) On estimation in relative survival. Biometrics 68:113–120PubMedCrossRef Perme MP, Stare J, Esteve J (2012) On estimation in relative survival. Biometrics 68:113–120PubMedCrossRef
3.
Zurück zum Zitat Dignam JJ, Kocherginsky MN (2008) Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 26:4027–4034PubMedCrossRef Dignam JJ, Kocherginsky MN (2008) Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 26:4027–4034PubMedCrossRef
4.
Zurück zum Zitat Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26:2389–2430PubMedCrossRef Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26:2389–2430PubMedCrossRef
5.
Zurück zum Zitat Gail MH (2008) Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies. Lifetime Data Anal 14:18–36PubMedCrossRef Gail MH (2008) Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies. Lifetime Data Anal 14:18–36PubMedCrossRef
6.
Zurück zum Zitat Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Bill-Axelsson BO, Damber JE, Hellström K, Hellström M, Holmberg E et al (2007) Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007(41):456–477CrossRef Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Bill-Axelsson BO, Damber JE, Hellström K, Hellström M, Holmberg E et al (2007) Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007(41):456–477CrossRef
7.
Zurück zum Zitat National Comprehensive Cancer Network (2010) Clinical practice guidelines in oncology, Prostate cancer, Version 1.2010 National Comprehensive Cancer Network (2010) Clinical practice guidelines in oncology, Prostate cancer, Version 1.2010
8.
Zurück zum Zitat D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420–2425PubMedCrossRef D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420–2425PubMedCrossRef
9.
Zurück zum Zitat Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516–1524PubMedCrossRef Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516–1524PubMedCrossRef
10.
Zurück zum Zitat Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P, Adolfsson J (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28:3448–3456PubMedCrossRef Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P, Adolfsson J (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28:3448–3456PubMedCrossRef
11.
Zurück zum Zitat Fang F, Fall K, Mittleman MA, Sparen P, Ye W, Adami HO, Valdimarsdóttir U (2012) Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med 366:1310–1318PubMedCrossRef Fang F, Fall K, Mittleman MA, Sparen P, Ye W, Adami HO, Valdimarsdóttir U (2012) Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med 366:1310–1318PubMedCrossRef
12.
Zurück zum Zitat Brenner H, Gefeller O, Hakulinen T (2004) Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 40:326–335PubMedCrossRef Brenner H, Gefeller O, Hakulinen T (2004) Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 40:326–335PubMedCrossRef
13.
Zurück zum Zitat Brenner H, Hakulinen T (2002) Advanced detection of time trends in long-term cancer patient survival: experience from 50 years of cancer registration in Finland. Am J Epidemiol 156:566–577PubMedCrossRef Brenner H, Hakulinen T (2002) Advanced detection of time trends in long-term cancer patient survival: experience from 50 years of cancer registration in Finland. Am J Epidemiol 156:566–577PubMedCrossRef
14.
Zurück zum Zitat Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat Med 23:51–64PubMedCrossRef Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat Med 23:51–64PubMedCrossRef
15.
Zurück zum Zitat Perme MP, Henderson R, Stare J (2009) An approach to estimation in relative survival regression. Biostatistics 10:136–146PubMedCrossRef Perme MP, Henderson R, Stare J (2009) An approach to estimation in relative survival regression. Biostatistics 10:136–146PubMedCrossRef
16.
Zurück zum Zitat Nelson CP, Lambert PC, Squire IB, Jones DR (2007) Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med 26:5486–5498PubMedCrossRef Nelson CP, Lambert PC, Squire IB, Jones DR (2007) Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med 26:5486–5498PubMedCrossRef
17.
Zurück zum Zitat Lambert PC (2009) Further development of flexible parametric models for survival analysis. Stata J 9:265–290 Lambert PC (2009) Further development of flexible parametric models for survival analysis. Stata J 9:265–290
18.
Zurück zum Zitat Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551–561PubMedCrossRef Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551–561PubMedCrossRef
19.
Zurück zum Zitat Lambert PC, Dickman PW, Nelson CP, Royston P (2010) Estimating the crude probability of death due to cancer and other causes using relative survival models. Stat Med 29:885–895PubMedCrossRef Lambert PC, Dickman PW, Nelson CP, Royston P (2010) Estimating the crude probability of death due to cancer and other causes using relative survival models. Stat Med 29:885–895PubMedCrossRef
20.
Zurück zum Zitat Brenner H, Arndt V (2005) Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 23:441–447PubMedCrossRef Brenner H, Arndt V (2005) Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 23:441–447PubMedCrossRef
21.
Zurück zum Zitat Holmberg L, Robinson D, Sandin F, Bray F, Linklater KM, Klint A, Lambert PC, Adolfsson J, Hamdy FC, Catto J, Møller H (2012) A comparison of prostate cancer survival in England, Norway and Sweden: a population-based study. Cancer Epidemiol 36:e7–e12PubMedCrossRef Holmberg L, Robinson D, Sandin F, Bray F, Linklater KM, Klint A, Lambert PC, Adolfsson J, Hamdy FC, Catto J, Møller H (2012) A comparison of prostate cancer survival in England, Norway and Sweden: a population-based study. Cancer Epidemiol 36:e7–e12PubMedCrossRef
22.
Zurück zum Zitat Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102:950–958PubMedCrossRef Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102:950–958PubMedCrossRef
23.
Zurück zum Zitat Hinchliffe SR, Abrams KR, Lambert PC (2012) The impact of under and over-recording of cancer on death certificates in a competing risks analysis: a simulation study. Cancer Epidemiol (Epub ahead of print). doi:10.1016/j.canep.2012.08.012 Hinchliffe SR, Abrams KR, Lambert PC (2012) The impact of under and over-recording of cancer on death certificates in a competing risks analysis: a simulation study. Cancer Epidemiol (Epub ahead of print). doi:10.​1016/​j.​canep.​2012.​08.​012
24.
Zurück zum Zitat Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102:1584–1598PubMedCrossRef Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102:1584–1598PubMedCrossRef
25.
Zurück zum Zitat Finnish Cancer Registry-Institute for Statistical and Epidemiological Cancer Research (2009) Cancer in Finland 2006 and 2007. Helsinki 2009. Publication No. 76 Finnish Cancer Registry-Institute for Statistical and Epidemiological Cancer Research (2009) Cancer in Finland 2006 and 2007. Helsinki 2009. Publication No. 76
26.
Zurück zum Zitat Koller MT, Raatz H, Steyerberg EW, Wolbers M (2011) Competing risks and the clinical community: irrelevance or ignorance? Stat Med 31:1089–1097PubMedCrossRef Koller MT, Raatz H, Steyerberg EW, Wolbers M (2011) Competing risks and the clinical community: irrelevance or ignorance? Stat Med 31:1089–1097PubMedCrossRef
27.
Zurück zum Zitat Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF et al (2012) The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer 118:5652–5662PubMedCrossRef Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF et al (2012) The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer 118:5652–5662PubMedCrossRef
28.
Zurück zum Zitat Brenner H, Hakulinen T (2003) On crude and age-adjusted relative survival rates. J Clin Epidemiol 56:1185–1191PubMedCrossRef Brenner H, Hakulinen T (2003) On crude and age-adjusted relative survival rates. J Clin Epidemiol 56:1185–1191PubMedCrossRef
29.
Zurück zum Zitat Pokhrel A, Hakulinen T (2008) How to interpret the relative survival ratios of cancer patients. Eur J Cancer 44:2661–2667PubMedCrossRef Pokhrel A, Hakulinen T (2008) How to interpret the relative survival ratios of cancer patients. Eur J Cancer 44:2661–2667PubMedCrossRef
30.
Zurück zum Zitat Fagerlin A, Zikmund-Fisher BJ, Ubel PA (2011) Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst 103:1436–1443PubMedCrossRef Fagerlin A, Zikmund-Fisher BJ, Ubel PA (2011) Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst 103:1436–1443PubMedCrossRef
31.
Zurück zum Zitat Lipkus IM (2007) Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Mak 27:696–713CrossRef Lipkus IM (2007) Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Mak 27:696–713CrossRef
32.
Zurück zum Zitat Lambert PC, Royston P (2009) Further development of flexible parametric models for survival analysis. Stata J 9:265–290 Lambert PC, Royston P (2009) Further development of flexible parametric models for survival analysis. Stata J 9:265–290
Metadaten
Titel
How can we make cancer survival statistics more useful for patients and clinicians: An illustration using localized prostate cancer in Sweden
verfasst von
Sandra Eloranta
Jan Adolfsson
Paul C. Lambert
Pär Stattin
Olof Akre
Therese M-L. Andersson
Paul W. Dickman
Publikationsdatum
01.03.2013
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 3/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0141-5

Weitere Artikel der Ausgabe 3/2013

Cancer Causes & Control 3/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.